Home » Stocks » Turmeric Acquisition

Turmeric Acquisition Corp. (TMPM)

Turmeric Acquisition currently trades with the ticker symbol TMPMU
Stock Price: $10.06 USD 0.00 (0.00%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 110.81M
Revenue (ttm) n/a
Net Income (ttm) -7,310
Shares Out 11.02M
EPS (ttm) 0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $10.06
Previous Close $0.00
Change ($) 0.00
Change (%) 0.00%
Day's Open 10.05
Day's Range 10.05 - 10.10
Day's Volume 35,128
52-Week Range 0.00 - 10.10

More Stats

Market Cap 110.81M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 11.02M
Float n/a
EPS (basic) n/a
EPS (diluted) 0.00
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income n/a
Net Income -7,310
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name Turmeric Acquisition Corp.
Country United States
CEO Luke Evnin

Stock Information

Ticker Symbol TMPM
Stock Exchange NASDAQ
Industry Blank Checks / SPAC
Unique Identifier NASDAQ: TMPM
IPO Date October 16, 2020


Turmeric Acquisition is a newly organized blank check company incorporated in August 2020 as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. While we may pursue an initial business combination opportunity in any industry or geographical location, we intend to capitalize on the ability of our management team to identify promising opportunities in the biotechnology sector, with an emphasis on oncology and rare disease therapeutics where our management has extensive experience in investing, operating and drug development. Our independent directors have extensive experience in clinical medicine, development and regulatory affairs, operations within academia as well as the healthcare and financial industry. All of our independent directors have led or been a part of leadership teams in biotechnology companies that have together generated billions in value for investors and helped develop numerous FDA approved drugs for patients. We believe that their breadth of experience will bolster our ability to thoroughly evaluate prospective candidates and successfully execute our initial business combination.